Captor Therapeutics Spolka Akcyjna
CTX
Rank in Stocks
#20289
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the... Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the blood, lymphatic system, and bone marrow; and CT-01, which also completed the Phase 1 clinical trials for the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.
Share Price
$13.83
Last synced: 2026-11-12
Market Cap
$86.85M
Change (1 day)
3.18%
Change (1 year)
6.84%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Captor Therapeutics Spolka Akcyjna (CTX)
Category
Healthcare
EPS for Captor Therapeutics Spolka Akcyjna (CTX)
EPS as of June 2026 TTM: $-1.97
According to Captor Therapeutics Spolka Akcyjna's latest financial reports, its current EPS (TTM) is $-1.97. At the end of 2025 the company had an EPS of $-2.12, a decrease compared to its 2024 EPS of $-2.01.
EPS history for Captor Therapeutics Spolka Akcyjna from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.97 | -7.30% |
| 2025 | $-2.12 | 5.42% |
| 2024 | $-2.01 | -48.07% |
| 2023 | $-3.87 | 96.70% |
| 2022 | $-1.97 | 0.50% |
| 2021 | $-1.96 | 86.87% |
| 2020 | $-1.05 | 48.58% |
| 2019 | $-0.70 | 93.73% |
| 2018 | $-0.36 | 2,186.16% |
| 2017 | $-0.02 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.99 | -49.63% |
US
|
|
| $15.66 | -896.82% |
US
|
|
| $-7.07 | 259.74% |
US
|
|
| $-5.29 | 169.17% |
AU
|
|
| $12.88 | -755.38% |
BE
|
Questions about Captor Therapeutics Spolka Akcyjna's earnings per share (EPS)
What is Captor Therapeutics Spolka Akcyjna's earnings per share (EPS)?
Captor Therapeutics Spolka Akcyjna's earnings per share (EPS) over the last twelve months is $-1.97, as of Jun 2026.
What was Captor Therapeutics Spolka Akcyjna's earnings per share (EPS) in 2025?
In 2025, Captor Therapeutics Spolka Akcyjna's earnings per share (EPS) was $-2.12, compared with $-2.01 in 2024.
How has Captor Therapeutics Spolka Akcyjna's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Captor Therapeutics Spolka Akcyjna's earnings per share (EPS) was highest in 2020 ($-1.05) and lowest in 2023 ($-3.87).
How does Captor Therapeutics Spolka Akcyjna's earnings per share (EPS) compare with similar companies?
Captor Therapeutics Spolka Akcyjna's earnings per share (EPS) ($-1.97) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.